Ebsteins anomaly of the tricuspid valve medical therapy: Difference between revisions
No edit summary |
|||
| Line 20: | Line 20: | ||
If there is [[atrial fibrillation]] with pre-excitation, treatment options include [[procainamide]], [[flecainide]], [[propafenone]], [[dofetilide]] and [[ibutilide]] since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical [[cardioversion]]. Intravenous [[amiodarone]] may also convert atrial fibrillation and/or slow the ventricular response. | If there is [[atrial fibrillation]] with pre-excitation, treatment options include [[procainamide]], [[flecainide]], [[propafenone]], [[dofetilide]] and [[ibutilide]] since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical [[cardioversion]]. Intravenous [[amiodarone]] may also convert atrial fibrillation and/or slow the ventricular response. | ||
[[Warfarin]] is recommended for patients with Ebstein’s anomaly with a history of paradoxical embolus or [[atrial fibrillation]]. | |||
Diuretics aid in flushing excess fluid from the body, thereby easing strain on the heart. | |||
Cardiac glycosides are used to maintain proper heart rhythm while increasing the strength of each contraction. | |||
==References== | ==References== | ||
Revision as of 20:42, 20 October 2012
|
Ebsteins anomaly of the tricuspid valve Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Ebsteins anomaly of the tricuspid valve medical therapy On the Web | |
|
American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve medical therapy | |
|
FDA on Ebsteins anomaly of the tricuspid valve medical therapy | |
|
CDC on Ebsteins anomaly of the tricuspid valve medical therapy | |
|
Ebsteins anomaly of the tricuspid valve medical therapy in the news | |
|
Blogs on Ebsteins anomaly of the tricuspid valve medical therapy | |
|
Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve medical therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] and Claudia P. Hochberg, M.D. [2]Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [3]
Overview
Medical management of patients with ebstein’s anomaly consists of giving supportive care, controlling heart rhythm with antiarrhythmic drugs, inotropic agents and diuretics for heart failure and anticoagulant in patients with history of atrial fibrillation and paradoxical embolus.
Medical Therapy
ACC / AHA 2008 Guidelines- Recommendation for Medical Therapy- Ebstein's Anomaly of the Tricuspid Valve(DO NOT EDIT)[1]
| Class I |
| "1.Anticoagulation with warfarin is recommended for patients with Ebstein’s anomaly with a history of paradoxical embolus or atrial fibrillation. (Level of Evidence: B) " |
Ebstein's cardiophysiology typically presents as an (antidromic) AV nodal reentrant tachycardia with associated pre-excitation. In this setting, the preferred pharmacological treatment agent is procainamide. Since AV-blockade may promote conduction over the accessory pathway, drugs like beta blockers, calcium channel blockers and digoxin are contraindicated.
If there is atrial fibrillation with pre-excitation, treatment options include procainamide, flecainide, propafenone, dofetilide and ibutilide since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical cardioversion. Intravenous amiodarone may also convert atrial fibrillation and/or slow the ventricular response.
Warfarin is recommended for patients with Ebstein’s anomaly with a history of paradoxical embolus or atrial fibrillation.
Diuretics aid in flushing excess fluid from the body, thereby easing strain on the heart.
Cardiac glycosides are used to maintain proper heart rhythm while increasing the strength of each contraction.
References
- ↑ Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.